Items 1 to 10 of 12 total
Display:
Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
---|---|---|---|---|---|---|
Flufenamic acid | 530-78-9 | sc-205699 sc-205699A sc-205699B sc-205699C | 10 g 50 g 100 g 250 g | $26.00 $77.00 $151.00 $303.00 | 1 | |
Flufenamic acid, a nonsteroidal anti-inflammatory drug, can inhibit AKR1C1 by competing for the enzyme's binding sites, preventing the reduction of steroids and other substrates, thus indirectly suppressing the enzyme's activity in steroid metabolism. | ||||||
Indomethacin | 53-86-1 | sc-200503 sc-200503A | 1 g 5 g | $28.00 $37.00 | 18 | |
Indomethacin acts as an inhibitor of prostaglandin synthesis enzymes and can indirectly inhibit AKR1C1 by altering prostaglandin levels, which may affect the enzyme's substrate specificity or availability, leading to reduced activity. | ||||||
Nonoxynol, n=9 | 26027-38-3 | sc-204821 sc-204821A | 50 g 100 g | $92.00 $157.00 | ||
Nonoxynol, n=9 is a surfactant used as a spermicide, can disrupt cellular membranes and potentially alter AKR1C1′s cellular environment, indirectly inhibiting its activity by affecting enzyme stability or cofactor availability. | ||||||
Mefenamic acid | 61-68-7 | sc-205380 sc-205380A | 25 g 100 g | $104.00 $204.00 | 6 | |
Mefenamic acid, another NSAID, can inhibit AKR1C1 by competing with substrates for binding to the enzyme, thereby reducing its ability to convert steroids and potentially affecting steroid hormone regulation. | ||||||
Ketoconazole | 65277-42-1 | sc-200496 sc-200496A | 50 mg 500 mg | $62.00 $260.00 | 21 | |
Ketoconazole, an antifungal agent, inhibits cytochrome P450 enzymes and can indirectly affect AKR1C1 activity by altering steroid biosynthesis upstream, thus impacting substrate availability for AKR1C1. | ||||||
Anastrozole | 120511-73-1 | sc-217647 | 10 mg | $90.00 | 1 | |
Anastrozole, an aromatase inhibitor, reduces estrogen synthesis and can indirectly inhibit AKR1C1 by decreasing the availability of estrogenic substrates, impacting the enzyme's role in estrogen metabolism. | ||||||
Trilostane | 13647-35-3 | sc-208469 sc-208469A | 10 mg 100 mg | $224.00 $1193.00 | 2 | |
Trilostane inhibits 3β-hydroxysteroid dehydrogenase, indirectly affecting AKR1C1 by altering the pool of steroid substrates available for reduction, potentially reducing the enzyme's activity in steroid metabolism. | ||||||
Finasteride | 98319-26-7 | sc-203954 | 50 mg | $103.00 | 3 | |
Finasteride, a 5α-reductase inhibitor, can indirectly inhibit AKR1C1 by reducing the production of dihydrotestosterone, thus affecting the balance of steroid substrates that AKR1C1 may act upon. | ||||||
Letrozole | 112809-51-5 | sc-204791 sc-204791A | 25 mg 50 mg | $85.00 $144.00 | 5 | |
Letrozole, another aromatase inhibitor, reduces estrogen levels and indirectly inhibits AKR1C1 by limiting the availability of estrogenic substrates, impacting the enzyme's metabolic activity. | ||||||
Sulindac | 38194-50-2 | sc-202823 sc-202823A sc-202823B | 1 g 5 g 10 g | $31.00 $84.00 $147.00 | 3 | |
Sulindac, by inhibiting cyclooxygenase, indirectly affects AKR1C1 activity by modifying prostaglandin synthesis, which could influence the enzyme's regulation or substrate specificity. |